ST Innovative Diagnostics

Monitoring Malignancies trough a Simple Blood Test

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in July 2022 by Esther Rabizadeh, ST Innovative Diagnostics operates with 1–10 employees. The company has secured $70,000 in total capital across one funding round.

Business overview

ST Innovative Diagnostics develops a novel blood-based malignancy monitoring test, leveraging research from Rabin Medical Center and Tel Aviv University. Its proprietary technology measures Fibrinogen Like Protein 2 (FGL2) activity in platelets, enabling non-invasive disease monitoring and relapse prediction across various malignancies. The company serves the Health Tech & Life Sciences sector, with applications in cancer diagnostics, medical devices, and early detection, and plans to expand into solid tumor monitoring and diagnosis.

Strategic signal

A May 2024 publication in journals.plos.org highlighted the presence and activity of Fibrinogen like protein 2 in platelets. This research underpins ST Innovative Diagnostics' core technology, validating the scientific basis for its blood-based malignancy monitoring test and signaling potential for further advancements in non-invasive cancer diagnostics.

Log in to access full profile

Company Intelligence Q&A

What is ST Innovative Diagnostics' core technology?
ST Innovative Diagnostics has developed a proprietary technology and kit that measures Fibrinogen Like Protein 2 (FGL2) activity in platelets for non-invasive malignancy monitoring and relapse prediction.
When was ST Innovative Diagnostics founded?
ST Innovative Diagnostics was founded in July 2022.
What is the primary focus of ST Innovative Diagnostics' product development?
The company's primary focus is on cancer diagnostics, specifically developing tests for early detection and monitoring of various malignancies, including Non-Hodgkin's Lymphoma, Prostate Cancer, and Cutaneous T-Cell Lymphoma, with plans to expand to solid tumor monitoring.
What was the key finding published in May 2024?
In May 2024, ST Innovative Diagnostics published research in journals.plos.org detailing the presence and activity of Fibrinogen like protein 2 in platelets, which is central to their diagnostic method.
What is the current stage of ST Innovative Diagnostics' product, LymFollow?
ST Innovative Diagnostics' product, LymFollow, is currently in the clinical trial stage, with proof-of-concept studies showing high correlation with PET/CT imaging in certain cancers.
Log in to access full profile